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Marta Azañedo,a Susana Garcı́a-Vargas,a Silvia Gutiérrez-Eisman,a,f Angeles Juarranz,g
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Ras proteins (H-, N-, and K-Ras) operate as molecular
switches in signal transduction cascades controlling cell
proliferation, differentiation, or apoptosis. The interac-
tion of Ras with its effectors is mediated by the effector-
binding loop, but different data about Ras location to
plasma membrane subdomains and new roles for some
docking/scaffold proteins point to signaling specificities
of the different Ras proteins. To investigate the molec-
ular mechanisms for these specificities, we compared an
effector loop mutation (P34G) of three Ras isoforms (H-,
N-, and K-Ras4B) for their biological and biochemical
properties. Although this mutation diminished the ca-
pacity of Ras proteins to activate the Raf/ERK and the
phosphatidylinositol 3-kinase/AKT pathways, the H-Ras
V12G34 mutant retained the ability to cause morpholog-
ical transformation of NIH 3T3 fibroblasts, whereas both
the N-Ras V12G34 and the K-Ras4B V12G34 mutants
were defective in this biological activity. On the other
hand, although both the N-Ras V12G34 and the K-Ras4B
V12G34 mutants failed to promote activation of the Ral-
GDS/Ral A/PLD and the Ras/Rac pathways, the H-Ras
V12G34 mutant retained the ability to activate these
signaling pathways. Interestingly, the P34G mutation
reduced specifically the N-Ras and K-Ras4B in vitro
binding affinity to Ral-GDS, but not in the case of H-Ras.
Thus, independently of Ras location to membrane sub-
domains, there are marked differences among Ras pro-
teins in the sensitivity to an identical mutation (P34G)
affecting the highly conserved effector-binding loop.
Ras proteins are critical components of signal transduction
pathways leading from cell-surface receptors to the control of
cell proliferation, differentiation, or death (1). The mammalian
genome contains three ras genes that encode highly related
proteins of 21 kDa termed H-Ras, N-Ras, and K-Ras with its
two variants, K-Ras4A and K-Ras4B, generated from two al-
ternative fourth exons. The three ras genes are concurrently
expressed in most mouse and human tissues (1). Normal Ras
proteins exist in equilibrium between an active (Ras-GTP) and
an inactive (Ras-GDP) state. The action of a variety of growth
factors increases the cellular concentration of Ras-GTP, and
the conformational change induced by GTP binding activates
Ras, thus enabling this GTPase to interact with its target
(“effector”) proteins. Once activated, Ras stimulates a multi-
tude of downstream signaling pathways. In the last years, a
wide range of proteins has been shown to specifically interact
with the Ras-GTP complex through the effector domain loop of
Ras, including Raf proteins, members of the Ral-GDS family,
PI3K,1 p120GAP, NF1, MEKK1, Rin1, AF-6, protein kinase C-,
and Nore1 (1).
The high degree of sequence homology, coupled with the
essentially identical ability of mutated forms of H-Ras, the two
K-Ras isoforms (4A and 4B), and N-Ras to cause transforma-
tion of NIH 3T3 fibroblasts and other cell types, have supported
the idea that all Ras proteins have the same role in vivo.
However, accumulating evidence supports the suggestion of
different roles of the three Ras homologues (1, 2). The embry-
onic lethality seen in the Kras, but not Hras or Nras, knockout
mice also provides support for this idea (3, 4). Similarly there
are differences in the specificity of the Ras-guanine nucleotide
exchange factor, thus several studies indicate that Ras-GRF1
activates H-Ras and R-Ras in vivo, but not N-Ras or K-Ras 4B
(5), or Sos induces GDP/GTP exchange on the three Ras iso-
forms in the hierarchy H-Ras  N-Ras  K-Ras (6). In addition
to this, N-Ras and H-Ras proteins can be reversibly palmitoy-
lated at one (Cys-181) or two (Cys-181 and Cys-184) cysteine
residues, respectively, whereas K-Ras possesses a polybasic
domain close to the C-terminal end, and these variations may
contribute to differences in trafficking (7), membrane associa-
tion, and effector pathway engagement between the three Ras
homologues (5). Indeed, recently the activation of H-Ras and
N-Ras proteins (but not K-Ras) in the Golgi apparatus and in
the endoplasmic reticulum (8, 9) has been described, depending
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on Ras-GRP and Ras-GRF proteins, respectively (10, 11). The
functional specificity in signaling by the three homologues is
also evidenced by the differences in the relative ability of H-Ras
versus K-Ras to activate the Raf and PI3K effector pathways
(12, 13). It has been suggested that K-Ras activates Rac more
efficiently than H-Ras (14), or that H-Ras and K-Ras induce
higher activation of NF-B than N-Ras (15). Furthermore, we
found recently that the cyclopentenone 15-deoxy-12,14-pros-
taglandin J2 binds to and activates H-Ras through the forma-
tion of a covalent adduct with this isoform that does not occur
with N-Ras or K-Ras 4B (16). However, in vitro binding assays
have failed to detect large affinity differences for each type of
Ras protein and any of the known putative downstream tar-
gets, with the exception of Sur8, a conserved Ras-binding pro-
tein with multiple leucine-rich repeats (17, 18). Sur8 specifi-
cally binds K-Ras and N-Ras but not H-Ras in vitro (17) and
displays a synergistic effect on the Ras-Raf-MEK-Erk pathway
probably by the stabilization of a ternary complex with Ras and
Raf-1 (19). Different in vitro binding protein studies have dem-
onstrated that specific point mutations at the effector domain
of Ras can reduce the interaction with Sur8 (P34G mutation),
with Raf-1 (E37G and Y40C mutations), with Ral-GDS (T35S
and Y40C mutations), or with PI3K (T35S and E37G muta-
tions) (17, 20). This suggests a key role for these residues in
how they affect the ability of Ras to interact with these effector
proteins.
Based on these observations, we hypothesized that the codon
34 of Ras may play a different role in H-, K-, and N-Ras,
thereby providing a distinct signaling capacity to each Ras
protein. Thus, in the present study we analyzed how replace-
ment of this residue, as in the P34G mutation, would impact
the signaling ability and transforming potential of the three
types of Ras proteins. We demonstrate that the H-Ras V12G34
mutant shows the same transforming effect in NIH 3T3 fibro-
blasts as that of the hyperactive version H-RasV12, but the
P34G mutation dramatically reduces the oncogenic activity of
N- and K-Ras4B proteins. Furthermore, we obtained evidence
showing that, independent of the effects on Sur8 binding, the
distinct biological behavior among these P34G mutants is dic-
tated by their specific ability to activate the Ral-GDS/Ral
A/PLD and the Ras/Rac pathways.
EXPERIMENTAL PROCEDURES
Cell Lines, Transfections, and Antibodies—NIH 3T3 fibroblasts were
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
Carlsbad, CA) supplemented with 10% calf serum (Invitrogen). COS1
and the human 293T (kidney keratinocyte) cell lines were maintained
in DMEM supplemented with 10% fetal calf serum (Invitrogen). Tran-
sient transfections in COS1 and 293T cells were performed with the
LipofectAMINE reagent (Invitrogen). Assays were done 48 h after
transfection. NIH 3T3 fibroblasts were transfected (transient or stable)
by the calcium phosphate precipitation technique (21). Morphologically
transformed foci were scored after 2–3 weeks in culture (21). Trans-
fected cells were also selected in medium supplemented, as appropriate,
with Geneticin 750 g/ml (Invitrogen). EGF was purchased from Sig-
ma-Aldrich. Monoclonal antibodies to phospho-MAPK (p-ERK1/p-
ERK2) and phospho-AKT proteins were purchased from New England
Biolabs (Beverly, MA). Rabbit polyclonal antisera to MAPK (ERK1/
ERK2) and AKT came from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA); monoclonal anti-p85 was from Upstate Biotechnology (Lake
Placid, NY); anti-Ral and anti-Rac1 monoclonal antibodies came from
BD Transduction (Lexington, KY); and anti-HA and anti-AU5 mono-
clonal antibodies came from Berkeley Antibody Co. (Berkeley, CA).
DNA Constructs—The plasmids pCEFL-KZ-HA, pCEFL-KZ-AU5,
pCEFL-KZ-AU5-H-Ras wt, pCEFL-KZ-AU5-K-Ras 4B wt, pCEFL-KZ-
AU5-N-Ras wt, pCEFL-KZ-AU5-H-RasV12, pCEFL-KZ-AU5-K-RasV-
12, pCEFL-KZ-AU5-N-RasV12, pGal4-Luc, and pCDNAIII-Gal4-Elk-1
were previously described (21). The effector dominant mutants V12G34,
V12S35, V12G37, and V12C40 of H-Ras, K-Ras4B, and N-Ras were
obtained by PCR from pCEFL-KZ-AU5-H-RasV12, pCEFL-KZ-AU5-K-
RasV12, and pCEFL-KZ-AU5-N-RasV12, using the specific primers and
providing sites BglII and NotI at the 5 and 3 ends, respectively. The
amplified products were then subcloned into BglII and NotI sites of
pCEFL-KZ-AU5. The sequences of the oligonucleotides utilized are
available upon request.
Immunocytochemistry—Cells on coverslips were fixed in 4%
paraformaldehyde in phosphate-buffered saline for 30 min and perme-
abilized with 0.2% Triton X-100 for 10 min. To detect F-actin, cells were
stained with tetramethylrhodamine B isothiocyanate-labeled phalloi-
din (TRITC-phalloidin, 10 g/ml, Sigma) for 1 h. The nuclei were
stained with Hoechst-33258 (H-33258, Riedel-de Haën).
Bacterial Expression of Fusion Proteins—The plasmids pGEX-RBD,
pGEX-RBD-Ral-GDS, pGEX-Ral-BD, and pGEX-PAK-CRIB containing
the Raf Ras-binding domain, the Ral-GDS Ras-binding domain, the Ral
A-binding domain, and the Rac1-binding domain, respectively, fused to
glutathione S-transferase (GST) were kindly provided by D. Shalloway,
J. L. Bos, and J. G. Collard. All GST fusion proteins were purified (from
Escherichia coli BL21(DE3) harboring these plasmids) following a
method previously described (21).
In Vitro Binding Assays—Transfected cells were lysed in cold lysis
buffer containing 25 mM HEPES, pH 7.5; 1% Triton X-100; 150 mM
NaCl; 10 mM MgCl2; 1 mM sodium orthovanadate (Na3VO4); 25 mM
NaF; 1 mM phenylmethylsulfonyl fluoride; 10 g/ml each of leupeptin,
aprotinin, and pepstatin A, and trypsin inhibitor. Nucleus-free super-
natants were incubated with the corresponding GST fusion protein on
glutathione-Sepharose beads and analyzed as previously described (21).
Kinase Assays—MAPK activity, in cells transfected with an
epitope-tagged MAPK (HA-ERK2 and HA-ERK1, referred to herein
as HA-ERK), was determined as previously described (21), using
myelin basic protein (Sigma) as a substrate. AKT assays, in cells
transfected with an epitope-tagged AKT (HA-AKT), were carried out
following a methodology described previously (16), using histone H2B
(Sigma) as a substrate. To measure the PI3K activity, the enzyme was
immunoprecipitated from cell extracts with anti-p85 following the
instructions of the supplier. The immunoprecipitate was resuspended
in 20 mM Hepes, pH 7.4; 0.1 mM EDTA; 100 mM NaCl; 1 mM dithio-
threitol; 0.5 mM phenylmethylsulfonyl fluoride; 2 g/ml aprotinin; 10
g/ml leupeptin; 2 g/ml 1-chloro-3-tosylamido-7-amino-2-hep-
tanone; 5 mM NaF; 1 mM NaVO4; 10 mM Na2MoO4; and 10 nM okadaic
acid, and 100 ng of protein were used to measure the activity of PI3K
using phosphatidylinositol (20 g) and 50 M [-32P]ATP as sub-
strates (22). In all in vitro kinase assays, some plaques were stimu-
lated for 10 min with EGF (100 ng/ml) and after PAGE or TLC, the
amount of phosphorylated substrates (myelin basic protein, histone
H2B, or lipids) was evaluated using a Fuji BAS1000 detector.
PLD Activity Assay—PLD activation was measured by its transphos-
phatidylating activity in the presence of 1-butanol to generate PtdBut
(23). NIH 3T3 fibroblasts or COS1 and 293T cells were grown in mul-
tiwell plates and labeled for 48 h in the presence of 1 Ci/ml of [14C]g-
lycerol (148 mCi/mmol). To assay PLD activity, labeling medium was
discarded and cells were washed with TD buffer (137 mM NaCl, 5 mM
KCl, 1 mM NaHPO4, 20 mM Tris/HCl, pH 7.4) and incubated for 30 min
in serum-free DMEM supplemented with 0.5% 1-butanol. Medium was
again removed, cells were then scraped in 1 ml of methanol, and plates
were washed once with 0.5 ml of methanol. The two methanol samples
were collected and mixed with 2 ml of chloroform and 1 ml of water. The
organic phases were dried in a 37 °C heating block under a nitrogen
stream. TLC using Silica Gel 60A plates (Whatman; LK6D) separated
the lipids. The plates were developed with the upper phase of a mixture
of ethyl acetate/iso-octane/acetic acid/water (90:50:20:100, v/v), visual-
ized, and quantified using an electronic-autoradiography system (In-
stant Imager, Packard). Counts in PtdBut were normalized for the
radioactivity incorporated into total lipids.
Reporter Gene Analysis—NIH 3T3 fibroblasts were transfected
with 0.6 g of constructs encoding for each Ras mutant, together with
16 ng of pCDNAIII-Gal4-Elk-1, 0.1 g of pRL-TK (a plasmid express-
ing the enzyme Renilla luciferase), and 0.3 g of the reporter plasmid
(pGal4-Luc). 18 h after transfection, NIH 3T3 fibroblasts were placed
in medium containing 0.1% calf serum, and 18 h later stimulated for
8 h with EGF (100 ng/ml). The assays were performed as described
previously (21).
RESULTS
P34G Mutation Abolishes the Transforming Activity of N-Ras
and K-Ras4B but Not of H-Ras—The interaction of Ras with its
effectors is mediated by the effector-binding loop, which spans
residues 32–40. Despite the fact that the amino acid sequence
corresponding to effector binding is identical between the Ras
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proteins, several studies have demonstrated that the three Ras
isoforms differentially activate Raf-1 and PI3K (12, 13). To
ascertain possible biological differences between the three Ras
isoforms, we tested the ability of mammalian expression vec-
tors driving expression of each isoform (with different effector-
binding loop mutations) to induce transforming foci after trans-
fection into NIH 3T3 fibroblasts. To this end, NIH 3T3 cells
were transfected with the hyperactive form (V12), or with the
effector dominant mutants V12C40, V12G37, V12S35 (which
only activate PI3K, Ral-GDS, and Raf-1, respectively) (20), and
V12G34 (showing reduced binding affinity to Sur8) (17) of the
three Ras isoforms (H-, N-, and K-Ras4B). We observed that
overexpression of the transfected, full-length ras V12 genes
consistently and reproducibly displayed transforming activity,
whereas this biological effect was not detected with the ras
V12C40, V12G37, or V12S35 mutants (Fig. 1A). The difference
in transforming potency among the Ras isoforms was further
manifested using the effector dominant mutant V12G34. As
shown in Fig. 1A, both the N-Ras V12G34 and the K-Ras4B
V12G34 mutants failed to cause transformation in NIH 3T3
fibroblasts when compared with their hyperactive forms (N-
Ras V12 and K-Ras4B V12). In sharp contrast, transfection
with H-Ras V12G34 resulted consistently in a number of trans-
formed foci that was similar to that produced by H-Ras V12
(Fig. 1A). Furthermore, actin stress fibers were dramatically
disrupted, and cells exhibited a high number of membrane
ruffles and lamellipodia, when H-Ras V12G34 or any Ras V12
was overexpressed in NIH 3T3 fibroblasts (Fig. 1B). However,
both the N-Ras V12G34- and the K-Ras4B V12G34-expressing
cells (Fig. 1B) did not display membrane ruffles and exhibited
a network of actin stress-fiber phenotypes that were similar to
that of the negative control (NIH 3T3 fibroblasts transfected
with the vector) and very close to that originated by any Ras
V12C40 (Fig. 1B) (24). According to results already published,
the different Ras V12C40 isoforms induced membrane ruffling
and lamellipodia, although more weakly than the correspond-
ing Ras V12 (20). Taken together, all these results suggest that
the H-Ras V12G34 mutant retained the ability to cause mor-
phological transformation of NIH 3T3 fibroblasts, whereas both
the N-Ras V12G34 and the K-Ras4B V12G34 mutants were
defective in this biological activity.
P34G Mutation Diminishes the Capacity of the Ras Proteins
to Activate the MAPK and the PI3K/AKT Signaling Path-
ways—To analyze whether the Ras/Raf/MEK/ERK pathway
was affected by the P34G mutation, COS1 cells were tran-
siently transfected with the different Ras mutants (V12,
V12G34, V12S35, V12G37, and V12C40), or with the vector as
negative control, and the ERK1/2 phosphorylation was ana-
lyzed by immunoblotting. As shown in Fig. 2A, although the
Ras V12 mutants induced high levels of ERK1/2 phosphoryla-
tion, the overexpression of any Ras V12G34 led to a significant
reduction of activated ERK1/ERK2. In all Ras isoforms, the
phospho-ERK levels induced by the Ras V12G34 mutants were
lower than that generated by their corresponding Ras V12 or
Ras V12S35 mutants and higher than that induced by the
other Ras effector mutants (V12G37 and V12C40) (Fig. 2A).
However, H-Ras V12G34 induced slightly higher ERK activa-
tion than N- and K-Ras4B V12G4 and lower than its corre-
sponding H-Ras V12S35 (-fold change, 3.4 versus 4.3) (Fig. 2A).
Same results were obtained using 293T or NIH 3T3 cell lines,
transiently or stably transfected, respectively (data not shown).
Likewise, and using an in vitro kinase assay, we observed a
sharp reduction of the ERK2 activity induced by all Ras
V12G34 mutants in comparison with the values from the cor-
responding Ras V12 (Fig. 2B). Again, the ERK2 activity in-
duced by the H-Ras V12G34 mutant was higher than the val-
ues generated by the N-Ras V12G34 and the K-Ras4B V12G4
mutants (Fig. 2B).
Ras can induce gene expression via the transcription factor
Elk-1 (1), which lies down-stream of the Ras/ERK cascade. To
confirm the results presented above, we carried out a reporter
assay using NIH 3T3 fibroblasts cotransfected with Ras con-
structs, together with a chimeric Gal4-Elk1 transcription factor
and the reporter plasmid TATA-Gal4-Luc. Fig. 2C shows the
results obtained in a set of experiments in which we measured
the induction of luciferase activity in starved conditions, using
the stimulation with EGF (100 ng/ml, 8 h) as positive control.
In accordance with the above ERK results, we have also de-
tected reduction Gal4-Elk1 activation by the Ras V12G34 and
Ras V12C40 mutants versus their corresponding hyperactive
forms (Ras V12) (Fig. 2C).
FIG. 1. Biological properties of Ras mutants. A, Transforming
activity of Ras mutants. NIH 3T3 fibroblasts were transfected with 50
ng of each type of Ras (H-, N-, or K-Ras4B), corresponding to the
hyperactive form (V12) or the effector dominant mutants (V12G34,
V12S35, V12G37, and V12C40) in pCEFL-KZ-AU5. As negative control
the cells were transfected with the vector (pCEFL-KZ-AU5). After 14
days the dishes were stained with Giemsa to score the transformed foci.
All plasmids DNAs produced similar numbers of marker-selectable
colonies. Results presented correspond to a representative experiment,
and similar results were obtained in four additional, separate experi-
ments performed in triplicate. B, effects of overexpressed Ras mutants
on actin organization. NIH 3T3 clones overexpressing different Ras
mutants (V12, V12G34, and V12C40) or transfected only with the vector
(pCEFL-KZ-AU5), as negative control, were serum-starved for 18 h and
then analyzed. Actin was detected with TRITC-phalloidin, and the
nuclei were stained by H-33258. The arrows indicate membrane ruffles.
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Similarly, the effect of P34G mutation was carried out on
another Ras effector cascade, the PI3K/AKT signaling path-
way. After transfection with different constructs (wt, V12,
V12G34) of each Ras isoform, serum-starved COS1 cells were
studied for PI3K activity using an in vitro kinase assay (Fig.
3A). In all cases, we detected lower PI3K activity in the Ras
V12G34 transfectants than their corresponding Ras V12. How-
ever, the Ras V12G34 mutants induced higher PI3K activity
than their wt versions (Fig. 3A). Likewise, and using an in vitro
kinase assay, we observed a reduction of the AKT/PKB activity
detected in all Ras V12G34 transfectants in comparison with
the values obtained of the corresponding Ras V12 transfectants
(Fig. 3B). Finally, COS1 cells were transiently transfected with
the different Ras mutants (V12, V12G34, V12S35, V12G37, and
V12C40), or with the vector as negative control, and AKT/PKB
phosphorylation was analyzed by immunoblotting (Fig. 3C).
Again, although Ras hyperactively (V12) induced high levels of
AKT phosphorylation, the overexpression of any Ras V12G34
led to a significant reduction of activated AKT/PKB (Fig. 3C).
The phospho-AKT levels induced by the Ras V12G34 mutants
were lower than that generated by their corresponding Ras
V12C40 mutants and only slightly higher than that induced by
the other Ras effector mutants (V12S35 and V12G37) (Fig. 3C).
The same results were obtained using NIH 3T3 and 293T cells
(data not shown). All these results indicate that the P34G
mutation diminished the capacity of Ras proteins to activate
the Ras/ERK/Elk-1 and PI3K/AKT signaling pathways.
P34G Mutation in N-Ras and K-Ras4B Diminishes the Ral-
GDS/Ral A Pathway Activation but Not in the Case of H-Ras—
The Ral-GDS/Ral A pathway has been characterized as the
third best understood Ras effector pathway (25). Again, COS1
cells were transfected with the different Ras mutants, or with
the vector as negative control, and they were incubated over-
night with serum-free medium. The activation of the Ral-GDS/
FIG. 2. Relative activation of the MAPK pathway by Ras mutants. A, COS1 cells were transfected with 1 g of each type of Ras (H-, N-,
or K-Ras4B), corresponding to the hyperactive form (V12) or the effector dominant mutants (V12G34, V12S35, V12G37, and V12C40) in
pCEFL-KZ-AU5. As negative control the cells were transfected with the vector (pCEFL-KZ-AU5). All cells were serum-starved for 18 h and then
the levels of phosphorylation of ERK (p42 and p44 proteins) were determined using specific anti-phospho- and full antibodies. The -fold change of
activation was estimated by densitometric analysis of filters. The values (given as arbitrary units) were normalized taking into consideration the
ERK protein levels of each sample as determined by immunoblot analysis. Results show a representative blot out of three. B, COS1 cells were
cotransfected with 1 g of ERK2 in pCEFL-KZ-HA and 1 g of each type of Ras (H-, N-, or K-Ras4B), corresponding to the hyperactive form (V12)
or the effector dominant mutants (V12G34 or V12C40) in pCEFL-KZ-AU5. As negative control the cells were transfected with the vector
(pCEFL-KZ-AU5). All cells were serum-starved for 18 h and then analyzed, as positive control cells transfected with the vector were stimulated
with EGF (100 ng/ml, 10 min). The histograms represent the ERK2 relative activity, expressed as -fold induction of [32P]myelin basic protein
normalized with respect to control cells and correspond to the average and standard deviation of five separate assays. C, NIH 3T3 fibroblasts were
cotransfected with the plasmid pcDNAIII-Gal4-Elk-1 encoding the Gal4-Elk1 fusion protein (containing the Gal4 DNA-binding domain and the
activation domain of Elk1), the plasmid pGal4-Luc containing the Photinus luciferase gene controlled by six copies of a Gal4-responsive element
and the plasmid pRL-TK containing the Renilla luciferase gene under control of the HSV-TK promoter region, together expression plasmids
pCEFL-AU5 containing the indicated Ras constructs described above. Cells were serum-starved and assayed 24 h later for luciferase activity. As
positive control cells transfected with the vector were stimulated with EGF (100 ng/ml, 8 h). The data represent Photinus luciferase activity
normalized by the Renilla luciferase activity present in each cellular lysate, expressed as -fold induction with respect to control cells, and are the
average and standard deviation of three separate assays performed in duplicate.
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Ral A pathway was analyzed by detection of Ral A-GTP levels
using a non-radioactive method by precipitation with a GST
fusion protein containing the Ral-binding domain of RIP1 (26).
As shown in Fig. 4A, although all Ras V12 mutants induced
high levels of Ral A-GTP, both the N-Ras V12G34 and the
K-Ras4B V12G34 mutants led to a significant reduction of the
activated Ral A pathway. In sharp contrast, H-Ras V12G34
induced Ral A-GTP levels similar to that of its hyperactive form
(H-Ras V12). Moreover, the activation of Ral A, due to the
V12G34 mutants of N-Ras and K-Ras4B, respectively, was of
the same level of that of their corresponding V12S35 and
V12C40 mutants (Fig. 4B), previously defined as being defi-
cient in the induction of the Ral-GDS/Ral A pathway (20).
Nevertheless, H-Ras V12G34 originated values of Ral A-GTP
similar to those of H-Ras V12G37 (Fig. 4B), absolutely active on
the Ral-GDS/Ral A pathway (20). Similar results were obtained
using 293T or NIH 3T3 cell lines, transiently or stably trans-
fected, respectively (data not shown). Thus, the P34G mutation
reduces the capacity to activate the Ral-GDS/Ral A pathway
only in the case of N-Ras and K-Ras4B, but not in the case
of H-Ras.
P34G Mutation in N-Ras and K-Ras4B Reduces the in Vitro
Binding Affinity to Ral-GDS, but Not in the Case of H-Ras—It
has been demonstrated that Ras proteins interact through the
effector domain with Raf (27), the p110 catalytic subunit of
PI3K (24), and Ral-GDS (25). Therefore, specific point muta-
tions at the effector domain of Ras can abolish the interaction
with Raf-1 (E37G and Y40C mutations), with Ral-GDS (T35S
and Y40C mutations), or with PI3K (T35S and E37G muta-
tions) (2). The P34G mutation also maps at the effector loop of
Ras proteins diminishing the binding affinity to Sur8 (17). In
view of our results about the effect of the P34G mutation on the
activation of Ral-GDS/Ral A pathway, we asked whether this
Ras mutation could be responsible for a different Ral-GDS
affinity with each Ras isoform. For this purpose, we carried out
in vitro binding assays of the different Ras mutants with the
FIG. 3. Relative activation of the PI3K/AKT pathway by Ras mutants. A, COS1 cells were transfected with 1 g of each type of Ras (H-,
N-, or K-Ras4B), corresponding to the wild type (WT), hyperactive form (V12), or the effector dominant mutant (V12G34) in pCEFL-KZ-AU5. As
negative control the cells were transfected with the vector (pCEFL-KZ-AU5). All cells were serum-starved for 18 h and then analyzed, and positive
control cells transfected with the vector were stimulated with EGF (100 ng/ml, 10 min). Histograms represent the PI3K relative activity, expressed
as -fold induction of [32P]phosphatidylinositol-phosphate normalized with respect to control cells, and correspond to the average and standard
deviation of five separate assays. B, COS1 cells were cotransfected with 1 g of AKT in pCEFL-KZ-HA and 1 g of each type of Ras (H-, N-, or
K-Ras4B), corresponding to the hyperactive form (V12) or the effector-dominant mutants (V12G34 or V1S35) in pCEFL-KZ-AU5. Negative control
cells were transfected with the vector (pCEFL-KZ-AU5). All cells were serum-starved for 18 h and then analyzed, and positive control cells
transfected with the vector were stimulated with EGF (100 ng/ml, 10 min). The histograms represent the AKT relative activity, expressed as -fold
induction of [32P]H2B normalized with respect to control cells, and correspond to the average and standard deviation of six separate assays. C,
COS1 cells were transfected with 1 g of each type of Ras (H-, N-, or K-Ras4B), corresponding to the hyperactive form (V12) or the effector dominant
mutants (V12G34, V12S35, V12G37, and V12C40) in pCEFL-KZ-AU5. As negative control the cells were transfected with the vector (pCEFL-KZ-
AU5). All cells were serum-starved for 18 h, and then the levels of phosphorylation of AKT using specific anti-phospho- and full antibodies were
determined. The -fold change of activation was estimated by densitometric analysis of filters. The values (given as arbitrary units) were normalized
taking into consideration the AKT protein levels of each sample as determined by immunoblot analysis. Results show a representative blot out of
three.
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FIG. 4. Relative activation of the Ral-GDS/Ral A pathway by Ras mutants. COS1 cells were transfected with 1 g of each type of Ras (H-,
N-, or K-Ras4B), corresponding to the hyperactive form (V12) or the effector dominant mutants (V12G34, V12S35, V12G37, and V12C40) in
pCEFL-KZ-AU5. As negative control the cells were transfected with the vector (pCEFL-KZ-AU5). A, all cells were serum-starved for 18 h and then
analyzed, and positive control cells transfected with the vector were stimulated with EGF (100 ng/ml, 10 min). Ral A-GTP was recovered from cell
lysates by binding to immobilized GST-Ral-BD and detected by immunoblotting with anti-Ral A monoclonal antibody (upper panel). The expression
levels of the transfected AU5-Ras constructs and the endogenous Ral A were detected by immunoblotting of the cell extracts with the corresponding
anti-AU5 and anti-Ral A monoclonal antibody, respectively (middle and lower panels). Results presented correspond to a representative
experiment, and similar results were obtained in three additional, separate experiments. Histograms represent the Ral A-GTP levels normalized
(by GelWoks Analyses) to Ral A levels and correspond to the average and standard deviation of four separate assays. B, histogram representation
of four separate experiments performed as above and including the rest of effector dominant mutants. As in A the histograms represent the Ral
A-GTP levels normalized (by GelWoks Analyses) to Ral A levels and correspond to the average and standard deviation of four separate assays.
P34G Abolishes the Transforming Activity of K-Ras and N-Ras 33485
Ras-binding domain (RBD) of Raf-1 and Ral-GDS. Thus, we
expressed as GST fusion proteins either RBD of both Ras
effector proteins. Cytoplasmic extracts from COS1 cells over-
expressing different Ras mutants (V12, V12G34, V12S35,
V12G37, and V12C40) were incubated with purified GST-RBD-
Raf 1 or GST-RBD-Ral-GDS proteins coupled to glutathione-
FIG. 5. In vitro binding assay of Ras mutants to GST-RBD-Raf 1 and GST-RBD-Ral-GDS fusion proteins in cell-free extracts. COS1
cell-free extracts, overexpressing the indicated AU5-Ras mutants, were incubated with 10 g of GST-RBD-Raf 1 (A) and GST-RBD-Ral-GDS (B)
proteins coupled to glutathione-Sepharose beads. After washing, cellular proteins bound to the beads were run in SDS alongside the corresponding
cell extract and immunoblotted against monoclonal AU5 antibody. Results presented correspond to a representative experiment, and similar
results were obtained in three additional, separate experiments. Histograms represent the relative binding affinity of each Ras effector dominant
mutant to RBD-Raf 1 (A) and RBD-Ral-GDS (B), normalized (by GelWoks Analyses) to Ras levels and expressed as a percentage of each Ras
V12-RBD binding, and correspond to the average and standard deviation of four separate assays.
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Sepharose beads, and the proteins bound to the beads were
analyzed by immunoblotting (Fig. 5). Whereas all Ras V12G34
mutants showed reduced affinity to RBD-Raf 1 (Fig. 5A), only
H-Ras V12G34 displayed an unaffected binding capacity to
RBD-Ral-GDS (Fig. 5B). Indeed, both the N-Ras V12G34 and
the K-Ras4B V12G34 mutants showed a drastically reduced
affinity to RBD-Ral-GDS, in sharp contrast to H-Ras V12G34
with a RBD-Ral-GDS binding affinity level close to H-Ras V12
and H-Ras V12G37 (Fig. 5B). These results could explain the
different levels of Ral-GDS/Ral A pathway activation detected
among the Ras V12G34 mutants (Fig. 4), as a consequence of
the N- and K-Ras4B V12G34 diminished interaction capacity
to Ral-GDS.
P34G Mutation in N-Ras and K-Ras4B Reduces Their Ca-
pacities to Activate PLD and Rac1 but Not in the Case of
H-Ras—Because phospholipase D (PLD) acts downstream of
Ral A (28), we tested whether the P34G mutation of Ras pro-
teins affected PLD activation differently. Thus, COS1 cells
were transfected with the different Ras mutants (V12 or
V12G34), or with the vector as negative control, and they were
incubated overnight with serum-free medium. As shown in Fig.
6, although all Ras V12 mutants induced high levels of PLD
activity, both the N-Ras V12G34 and the K-Ras4B V12G34
mutants failed to activate PLD. By contrast, H-Ras V12G34
promoted similar levels of PLD activity to those of its hyperac-
tive form (H-Ras V12) (Fig. 6). Same results were obtained
using 293T or NIH 3T3 cell lines, transiently or stably trans-
fected, respectively (data not shown). These results are in ac-
cordance with the possibility that the P34G mutation reduces
the capacity to activate the Ral-GDS/Ral A/PLD pathway only
in the case of N-Ras and K-Ras4B, but not in the case of H-Ras.
As it was denoted, NIH 3T3 fibroblasts overexpressing H-
Ras V12G34 or any Ras V12 exhibited high number of mem-
brane ruffles and lamellipodia (Fig. 1B), whereas N- or
K-Ras4B V12G34-expressing NIH 3T3 cells did not display this
cortical actin rearrangements. Given that Rac (another mem-
ber of the Ras superfamily of GTPases) functions downstream
of Ras in pathways that stimulate membrane ruffling (29) and
growth transformation (30), we studied the effect of the P34G
mutation on the Ras activation of Rac. The detection of Rac-
GTP levels was carried out using a non-radioactive method by
precipitating a GST fusion protein containing the Rac-binding
domain of PAK-CRIB (31). Following the same approach used
above we observed that, although the P34G mutation did not
affect the Ras in vivo binding affinity to Tiam1 (data not
shown), both the N-Ras V12G34 and the K-Ras4B V12G34
mutants failed to promote activation of Rac, whereas the H-Ras
V12G34 mutant retained the ability to activate this GTPase
(Fig. 7).
N-Ras V12G37 and K-Ras4B V12G37 Rescue the Transform-
ing Activity of Their Corresponding V12G34 Mutants—In ac-
cordance with the results obtained, if our hypothesis, that the
diminished transforming activity of N- and K-Ras4B V12G34
was due to the Ral-GDS/Ral A/PLD pathway, is correct, a
complementation effect should be observed with the V12G37
mutants. To test this hypothesis we carried out an assay of
transforming activity in NIH 3T3 fibroblasts. To this end, the
N- and K-Ras4B effector dominant mutants (V12S35, V12G37,
and V12C40) were transfected alone or in cotransfection with
its corresponding V12G34 mutant (Fig. 8A). Focus formation
was expressed as a percentage of the maximum focus-forming
activity of each Ras V12 (Fig. 8B). Only the cotransfectants
V12G34 plus V12G37 generated a statistically significant num-
ber of transforming foci (higher than the simple addition orig-
inated by each one), which partially rescued the transforming
activity of each hyperactive (V12) mutant (Fig. 8B). Moreover,
the ability to induce focus formation correlated with the effi-
ciency of the corresponding cotransfectants in proliferating in
semisolid agar (data not shown). These data suggest that both
the N-Ras V12G34 and the K-Ras4B V12G34 mutants were
unable to cause morphological transformation of NIH 3T3 fi-
broblasts due to the diminished activation of the Ral-GDS/Ral
A/PLD pathway.
DISCUSSION
In this study, we have investigated the differential impact of
the effector loop mutation P34G on the biological activity of the
three Ras isoforms, in the context of a hyperactive mutation
(G12V). Although this P34G mutation maps to a region with
absolute homology among all Ras isoforms, we have observed
FIG. 6. PLD activation by Ras mu-
tants. COS1 cells were transfected with 1
g of each type of Ras (H-, N-, or
K-Ras4B), corresponding to the hyperac-
tive form (V12) or the effector dominant
mutant (V12G34) in pCEFL-KZ-AU5. As
negative control the cells were trans-
fected with the vector (pCEFL-KZ-AU5).
All cells were serum-starved for 18 h and
then analyzed as positive control cells
transfected with the vector were stimu-
lated with EGF (100 ng/ml, 10 min). A,
PLD activity was tested as described un-
der “Experimental Procedures.” Results
presented correspond to a representative
experiment, and similar results were ob-
tained in four additional, separate exper-
iments. B, the histograms represent the
PLD relative activity, expressed as -fold
induction of [14C]PtdBut normalized with
respect to control cells and are the aver-
age and standard deviation of five sepa-
rate assays.
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different biological phenotypes and different biochemical ef-
fects on the signaling pathways downstream of Ras. Thus, we
found that, although the H-Ras V12G34 mutant retained the
ability to cause morphological transformation of NIH 3T3 fi-
broblasts, both the N-Ras V12G34 and the K-Ras4B V12G34
mutants were completely devoid of transforming activity.
Therefore, the actin cytoskeleton of NIH 3T3 fibroblasts over-
expressing H-Ras V12G34 or any Ras V12 was identical, but
not in the case of cells overexpressing N- or K-Ras4B V12G34,
which showed an actin cytoskeleton typical of untransformed
cells. According to a previous study (20), we found that all Ras
V12S35 and V12G37 mutants failed to induce cortical actin
rearrangements (ruffling or lamellipodia), whereas all Ras
V12C40 mutants induced membrane ruffling but more weakly
than their counterpart Ras V12. Likewise, we detected that
only H-Ras V12G34 induced ruffling and lamellipodia, but not
N- or K-Ras4B V12G34. Previously it has been described that
H-Ras V12G34 produced transforming foci in 69BUR cells, but
not in Rat2 cells (32, 33), and it was unable to induce differen-
tiation of PC12 cells into neuronal cells (32, 34). However, this
behavior is not unusual, because oncogenic versions of Ras
cause cell transformation in some cells but growth inhibition in
others, and they promote the differentiation of some cells yet
block the differentiation of others (2). Thus, it is critical to
compare the biological activity of V12G34 mutants of each Ras
isoform into the same cellular background.
Ras proteins cause a diverse spectrum of cellular responses
that might require multiple effectors. Thus, Ras inhibition of
suspension-induced apoptosis (anoikis) is dependent on Ras
activation of PI3K but not of Raf (35, 36). Conversely, Ras
induction of senescence in primary fibroblasts appears to be
facilitated by Raf activation alone (37). Frequently, the cooper-
ative interaction of multiple effectors is required to originate
specific actions of Ras, such as the cell cycle progression (38).
Indeed, Ras inhibition of myoblast differentiation depends on
several effectors, including Raf and Ral-GDS, as well as uni-
dentified effectors (39).
Given that the transformed phenotype by oncogenic Ras
requires multiple signaling pathways (20), we have analyzed
the three main pathways downstream of Ras. In all Ras iso-
forms, the P34G mutation reduced the capacity to activate the
Raf/MEK/ERK and the PI3K/AKT signaling pathways. How-
ever, the activation of these pathways was not abolished com-
pletely, we detected that cells overexpressing any Ras V12G34
showed higher activation of these pathways than the negative
control or cells overexpressing Ras wt (data not shown). Indeed,
the Ras V12G34 mutants induced levels of phospho-ERK
higher than their corresponding V12G37 and V12C40 mutants
and slightly lower (especially in the case of H-Ras V12G34)
than their corresponding V12S35 mutants. However, only in
the case of N- and K-Ras4B did the P34G mutation diminish
the capacity to activate the Ral-GDS/Ral A/PLD pathway,
whereas H-Ras V12G34 was unaffected in its ability to induce
this pathway. This effect was a consequence of the different
binding affinity to Ral-GDS; specifically both the N-Ras
V12G34 and the K-Ras4B V12G34 mutants showed very di-
minished in vitro binding affinity to Ral-GDS-RBD in compar-
ison with their counterparts Ras V12. In contrast, both H-Ras
V12G34 and H-Ras V12 displayed similar affinity to Ral-GDS-
RBD. This is the first description of a mutation in the effector
loop of Ras with different impact on the in vitro affinity to an
effector protein (Ral-GDS), depending of the Ras protein iso-
form. Because the effector loop is a domain with absolute ho-
mology among all Ras isoforms, the explanation could be the
influence of the hypervariable C-terminal region of Ras, be-
cause it has been proposed for its different ability between
K-Ras and H-Ras to activate in vivo Raf-1 and PI3K (12). The
N-terminal 85 residues of all Ras isoforms are identical and
contain the two switch regions that undergo changes on GTP
binding; in addition the next 80 amino acids are 95% conserved,
and the major differences between Ras proteins are confined to
the hypervariable region between residues 166 and 185. How-
ever, the role of the hypervariable region in influencing the
interaction of Ras with its effector protein in vivo has been
related to different plasma location signals (7, 12), whereas
here we observed differences of in vitro binding independently
of the mechanisms of plasma attachment. On the other hand,
although the structures of the RBD are similar, the thermo-
dynamics of the interactions Ras/Raf-RBD and Ras/Ral-GDS-
RBD are quite different (40), suggesting a different mode of
binding that is not obvious from the three-dimensional struc-
ture (40), such as might occur with our case.
Probably, future works using a molecular dynamic approach
by comparison of the three Ras V12G34 structures could dis-
cern a plausible and mechanistic explanation for these results.
Furthermore, the P34G mutation reduces the in vitro binding
affinity of Ras to Sur8 (17), and this protein displays a syner-
gistic effect on the Ras-Raf-MEK-Erk pathway by stabilizing a
ternary complex with Ras and Raf-1 (19). Notwithstanding, we
have not detected any interaction (in vitro and in vivo) between
FIG. 7. Relative Rac activation by Ras mutants. COS1 cells were
transfected with 1 g of each type of Ras (H-, N-, or K-Ras4B), corre-
sponding to the hyperactive form (V12) or the effector dominant mutant
(V12G34) in pCEFL-KZ-AU5. As negative control, the cells were trans-
fected with the vector (pCEFL-KZ-AU5). All cells were serum-starved
for 18 h and then analyzed. Rac-GTP was recovered from cell lysates by
binding to immobilized GST-PAK-CRIB and detected by immunoblot-
ting with anti-Rac monoclonal antibody (upper panel). The expression
levels of the transfected AU5-Ras constructs and the endogenous Rac
were detected by immunoblotting of the cell extracts with the corre-
sponding anti-AU5 and anti-Rac monoclonal antibody, respectively
(middle and lower panel). Results presented correspond to a represent-
ative experiment, and similar results were obtained in four additional,
separate experiments. Histograms represent the Rac-GTP levels nor-
malized (by GelWoks Analyses) to Rac levels, are expressed as a per-
centage of each Ras V12-induced Rac activation, and correspond to the
average and standard deviation of five separate assays. Similar results
were obtained using stably transfected NIH 3T3 fibroblasts.
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Sur8 and Ral-GDS2 that could explain the different binding of
Ras V12G34 mutants to this effector protein. Curiously, in all
Ras isoforms, the P34G mutation reduced the in vitro affinity
to Raf-RBD to a lesser extent than the T35S mutation, which
has been proposed to affect the PI3K and Ral-GDS pathways
but not the Raf pathway (20). When we analyzed the Raf/MEK/
ERK activation, all Ras V12G34 mutants (especially N- and
K-Ras4B V12G34) induce lower ERK activity than their corre-
sponding V12S35 mutants. This result could be due to reduc-
tion of the stability of the Ras-Raf in vivo complex in the
V12G34 mutants (by absence of ternary complex with Sur8)
(19). In accord with this hypothesis we found that ectopic
overexpression of Sur8 increased the amount of phospho-ERK
induced by any Ras V12G34 to the same levels generated by
Ras V12S35.2 Given that Sur8 was described as a protein that
specifically binds to N-Ras and K-Ras but not to H-Ras (17), the
results could also be consistent with the idea that N- and
2 J. L. Oliva, N. Zarich, N. Martı́nez, R. Jorge, A. Castrillo,
M. Azañedo, S. Garcı́a-Vargas, S. Gutiérrez-Eisman, A. Juarranz,
L. Boscá, J. S. Gutkind, and J. M. Rojas, unpublished results.
FIG. 8. Focus formation assay in NIH 3T3 fibroblasts cotransfected with different N and K-Ras4B mutants. A, NIH 3T3 fibroblasts
were transfected with 25 ng of N- or K-Ras4B, corresponding to the hyperactive form (V12) or the effector dominant mutants (V12G34, V12S35,
V12G37, and V12C40) in pCEFL-KZ-AU5 or cotransfected with the corresponding V12G34 plus V12S35, V12G34 plus V12G37, or V12G34 plus
V12C40 (25 ng plus 25 ng, in all cases). As negative control the cells were transfected with the vector (pCEFL-KZ-AU5). After 14 days the dishes
were stained with Giemsa to score the transformed foci. All plasmids DNAs produced similar numbers of marker-selectable colonies. B, focus
formation was then quantitated and expressed as a percentage of each Ras V12-induced focus formation. Histograms correspond to the average and
standard deviation of five separate assays performed in triplicate.
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K-Ras4B require interaction with Sur8 for their efficient trans-
forming activity, whereas H-Ras does not in the biological
system used in this study. However, some data appear to sug-
gest that Sur8 also binds to H-Ras protein (19).2
Finally, we found that only the cotransfection of NIH 3T3
fibroblasts with N-Ras V12G34 and N-Ras V12G37, or
K-Ras4B V12G34 and K-Ras4B V12G37, partially rescued the
number of transforming foci induced by N-Ras V12 or K-Ras4B
V12, respectively. This suggests that the N- and K-Ras4B
V12G34 mutants were devoid of transforming activity due to
the diminished activation of the Ral-GDS/Ral A/PLD pathway.
The transformed phenotype by oncogenic Ras requires at least
the activity of two Ras effectors pathways (20), for this reason
the Ras V12G37 mutants (working in the Ral-GDS/Ral A path-
way, but failing in both the Raf/MEK/ERK and the PI3K/AKT
pathways) are unable to induce transforming foci as the Ras
V12S35 and V12C40 mutants. Nevertheless, the activation of
Raf/MEK/ERK pathway induced by each Ras V12G34 was
higher than that induced by Ras V12G37 or V12C40, and
similarly the activation of the PI3K/AKT pathway generated by
each Ras V12G34 was also higher than that led by Ras V12G37
or V12S35. Probably, the transforming activity depends on a
minimum of Ras downstream pathways activation. Thus, both
the N-Ras V12G34 and the K-Ras4B V12G34 mutants gener-
ated some levels of PI3K/AKT and Raf/MEK/ERK activation,
which, together the Ral-GDS/Ral A/PLD activity induced by
their corresponding V12G37 mutants, were enough to produce
transforming foci in the cotransfection assays. Indeed, H-Ras
V12G34 would be able to induce transforming foci in NIH 3T3
fibroblasts due to the perfect functionality of the Ral-GDS/Ral
A/PLD pathway (as that originated by H-Ras V12), and the
high activity of the Raf/MEK/ERK pathway (together a light
activation of the PI3K/AKT pathway). Additionally, we have
also detected H-Ras V12G34 activation of Rac, whereas both
the N-Ras V12G34 and the K-Ras4B V12G34 mutants were
unable to activate this GTPase. It is known that Rac stimulates
membrane ruffling (29) and growth transformation (30), and it
has been indicated that Rac-GTP levels are elevated in H-Ras
V12-transformed NIH 3T3 cells (31). Furthermore, it is possi-
ble that the decreased PLD activation observed with the P34G
mutation, for N- and K-Ras 4B, might reflect impaired activa-
tion of Rac, as well as Ral, because Rac (like Ral) has been
shown to be upstream of PLD (28, 30, 31). Although several
studies support that Ras might activate Rac by PI3K-depend-
ent (41) or Tiam1-dependent mechanisms (31), here we have
not found significant differences between PI3K activity and
Tiam1 affinity among Ras V12G34 mutants. We can only spec-
ulate at this moment about the reasons for the different behav-
ior of the Ras V12G34 mutants on Rac activation. One expla-
nation may reside in the perfect functionality of the Ral-GDS/
Ral A/PLD pathway induced by H-Ras V12G34; i.e. that it did
not occur with N-Ras/K-Ras V12G34 mutants. There is circum-
stantial evidence that Ral A may have a function in regulating
the cytoskeleton through its interaction with RIP1, a GTPase-
activating protein specific for the small GTPases Cdc42 and
Rac (26). Furthermore, it has been denoted that Ras V12G37
mutants elicit the same Rac-GTP levels as does Ras V12 (31),
suggesting that the Ral-GDS/Ral A pathway might also medi-
ate Ras activation of Rac (1). Indeed, the activated Ras-related
protein TC21 induces PI3K activity, but not the Ral-GDS/Ral A
pathway, and, unlike Ras, TC21 does not activate Rac (42).
Alternatively, the different Rac activation may also reflect the
complex biological localization of Ras proteins. Consistent with
this idea, it has been demonstrated that Ras proteins localized
in plasma membrane, endoplasmic reticulum, and the Golgi
apparatus can signal differently (8). Further work will allow us
to answer this question and to get a comprehensive view of the
different mechanisms that directly mediates Ras activation
of Rac.
Although all Ras isoforms qualitatively activate the same
effector pathways, we have shown here that there are marked
differences in the sensitivity to an identical mutation in their
highly conserved effector loop, which are likely independent
of the type of plasma membrane attachment of each Ras.
These differences may account for the selective activation of
different Ras in specific human tumors. Therefore, we found
that the cyclopentenone, 15-deoxy-12,14-prostaglandin J2,
binds to and activates H-Ras through the formation of a
covalent adduct with the cysteine 184 of this isoform and that
it does not occur with N-Ras or K-Ras 4B (16). Ras-dependent
inputs can be activating or inhibitory signals that reach the
cell cycle regulatory machinery using different downstream
pathways (38). Therefore, Ras probably utilizes distinct ef-
fectors with different combinations of pathways (in some
cases depending on cell context) to originate its multiple and
diverse biological actions.
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